GE Healthcare and Germfree working on modular bioprocessing solution

The project is a rapidly deployable process-ready cleanroom and bioprocessing platforms for biotherapeutics such as gene therapy

Germfree modular bioprocessing environment

GE Healthcare and Germfree are joining expertise to develop a fully integrated, expandable manufacturing solution for emerging biotherapeutics, including gene therapy. The two US companies are both already involved in the construction of modular manufacturing platforms.

The manufacturing solution will feature a Germfree modular bioprocessing environment based on GE Healthcare's proprietary design and equipped with FlexFactory, GE Healthcare's integrated single-use biomanufacturing platform. This will be the latest addition to GE Healthcare's KUBio prefabricated manufacturing facility offering.

With more than 700 cell and gene therapies currently in clinical trials, demand exceeds supply. The collaboration with Germfree represents a significant contribution to increase capacity and capability in the gene therapy market.

"With Germfree, we will bring reliable and scalable technologies for modular solutions to the gene therapy space," said Olivier Loeillot, General Manager of BioProcess at GE Healthcare. "Modular capabilities can reduce timelines, lower capital and operating costs, as well as give flexibility for potential expansion."

Carol Houts, Germfree's VP of Quality and Business Strategy said: "The collaboration with GE Healthcare provides rapidly deployable process-ready cleanroom and bioprocessing platforms to an industry where resource constraints limit the progress of emerging biotherapeutics. Germfree has longstanding global expertise in producing biocontainment environments and biotherapeutics cleanroom solutions."

Germfree is a biotech company pioneering manufacturing of process ready cleanroom facilities. The solution developed by Germfree and GE Healthcare will provide tools and technology for biomanufacturing in an integrated and flexible Good Manufacturing Practice (GMP) environment. This is expected to speed novel therapies to market and accelerate the accessibility of personalised medicines.

Companies